Measures used in specifying psoriasis lesion(s), global disease and quality of life: A systematic review

被引:31
作者
Garduno, Javier
Bhosle, Monali J.
Balkrishnan, Rajesh
Feldman, Steven R.
机构
[1] Wake Forest Univ, Sch Med, Dept Dermatol, Ctr Dermatol Res, Winston Salem, NC 27157 USA
[2] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA
[3] Sch Publ Hlth, Columbus, OH 43210 USA
关键词
disease severity; outcomes; PASI; psoriasis; quality of life;
D O I
10.1080/09546630701271807
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective: To assess which measures are utilized to quantify lesions, disease severity, and quality of life in the current literature on psoriasis vulgaris. Methods: A MEDLINE search was performed with the keyword 'psoriasis' and the following limits 'All Adult: 19+ years', 'published in the last 5 years', 'English', 'Randomized Controlled Trial', and 'Humans'. The 'Methods' section of the individual articles were reviewed for inclusion criteria that described the study participants' state of psoriasis or disease generalization at baseline, methods used to classify or measure psoriasis during the study, the primary and secondary endpoints, and the quality of life measures utilized in each study. Results: A search resulted in a total of 180 articles, out of which 134 were utilized for the review. The criteria most commonly utilized were 'moderate to severe psoriasis', 'BSA >= 10%', 'mild to moderate psoriasis', and 'severe psoriasis'. PASI was the most commonly used measure to describe the extent of psoriasis. The most common QoL measure used was DLQI, being used in 54.8% of the articles that used some form of QoL measure/s. Discussion: Various measures are being utilized for the same purpose of generalizing disease/lesion severity and determining 'quality of life'.
引用
收藏
页码:223 / 242
页数:20
相关论文
共 177 条
[51]   Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris [J].
Gollnick, H ;
Altmeyer, P ;
Kaufmann, R ;
Ring, J ;
Christophers, E ;
Pavel, S ;
Ziegler, J .
DERMATOLOGY, 2002, 205 (01) :46-53
[52]  
Goodfield M, 2004, J Dermatolog Treat, V15, P14, DOI 10.1080/09546630310017843
[53]   Treatment of psoriasis with alefacept - Correlation of clinical improvement with reductions of memory T-Cell counts [J].
Gordon, KB ;
Vaishnaw, AK ;
O'Gorman, J ;
Haney, J ;
Menter, A .
ARCHIVES OF DERMATOLOGY, 2003, 139 (12) :1563-1570
[54]  
Gordon KB, 2004, JAMA-J AM MED ASSOC, V291, P1070
[55]   Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial [J].
Gottlieb, AB ;
Evans, R ;
Li, S ;
Dooley, LT ;
Guzzo, CA ;
Baker, D ;
Bala, M ;
Marano, CW ;
Menter, A .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 51 (04) :534-542
[56]   Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial [J].
Gottlieb, AB ;
Griffiths, CEM ;
Ho, VC ;
Lahfa, M ;
Mrowietz, U ;
Murrell, DF ;
Ortonne, JP ;
Todd, G ;
Cherill, R ;
Marks, I ;
Emady-Azar, S ;
Paul, CF .
BRITISH JOURNAL OF DERMATOLOGY, 2005, 152 (06) :1219-1227
[57]   A randomized trial of etanercept as monotherapy for psoriasis [J].
Gottlieb, AB ;
Matheson, RT ;
Lowe, N ;
Krueger, GG ;
Kang, S ;
Goffe, BS ;
Gaspari, AA ;
Ling, M ;
Weinstein, GD ;
Nayak, A ;
Gordon, KB ;
Zitnik, R .
ARCHIVES OF DERMATOLOGY, 2003, 139 (12) :1627-1632
[58]   CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept:: Results of a randomized study [J].
Gottlieb, AB ;
Casale, TB ;
Frankel, E ;
Goffe, B ;
Lowe, N ;
Ochs, HD ;
Roberts, JL ;
Washenik, K ;
Vaishnaw, AK ;
Gordon, KB .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (05) :816-825
[59]   Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis [J].
Gottlieb, AB ;
Chaudhari, U ;
Mulcahy, LD ;
Li, S ;
Dooley, LT ;
Baker, DG .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 48 (06) :829-835
[60]   The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions [J].
Gottlieb, AB ;
Ford, RO ;
Spellman, MC .
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2003, 7 (03) :185-192